Oligomers of grape-seed procyanidin extract activate the insulin receptor and key targets of the insulin signaling pathway differently from insulin
Semaglutide (Ozempic, Wegovy, Rybelsus) by Novo Nordisk is the established standard of care, with FDA approval since 2017, proven cardiovascular benefit, and availability in both injectable and oral formulations
A joint position paper by the World Heart Federation and World Obesity Federation, European Journal of Preventive Cardiology [accessed 16 October 2025] Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial, JAMA Psychiatry [accessed 16 October 2025] Once-Weekly Semaglutide in Adults with Overweight or Obesity, NEJM [accessed 16 October 2025] Phase 3 Trial of Semaglutide in Metabolic DysfunctionAssociated Steatohepatitis, NEJM [accessed 16 October 2025] Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes, NEJM [accessed 16 October 2025] The Effect of Semaglutide on Blood Pressure in Patients without Diabetes: A Systematic Review and Meta-Analysis, Journal of Clinical Medicine [accessed 16 October 2025] Wegovy 2.4 mg, FlexTouch solution for injection in pre-filled pen, emc [accessed 16 October 2025] Weight loss jab 'could reduce heart attack risk', BBC News [accessed 16 October 2025] Patient Reviews Related Weight Loss Treatments Further Reading on Weight Loss Do Appetite Suppressants Work
The dose for weight loss is usually lower than the dose used for diabetes management
Well cover all the important details during your initial consultation, but please note that this medication is given on a tapered basis
